BASF completes Orgamol acquisition
The acquisition includes Orgamol's headquarters in Evionnaz, Switzerland and a second Orgamol production site in Saint-Vulbas, France. Orgamol employs a total staff of about 450 at the two sites.
03/10/05 The acquisition of the Swiss fine chemicals company, Orgamol S.A., by BASF Aktiengesellschaft has been finalised. The regulatory authorities issued their unconditional approval of the transaction.
The acquisition includes Orgamol's headquarters in Evionnaz, Switzerland and a second Orgamol production site in Saint-Vulbas, France. Orgamol employs a total staff of about 450 at the two sites.
"The acquisition strengthens our position in the attractive pharmaceutical contract manufacturing market on a sustainable basis. The next step is to work together to integrate Orgamol's activities rapidly and successfully into our existing portfolio," said Dr. Wolfgang Büchele, head of BASF's Fine Chemicals division.
Orgamol is an important player in the contract manufacturing market and supplies exclusive ingredients to customers in the pharmaceutical industry. The acquisition puts BASF among the top 10 global providers in this field. BASF's global contract manufacturing business will be managed from Switzerland.
